Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.
LeukemiaJul 6, 2026 (epub)
Hannah C Beird, Sankaranarayanan Kannan, Jingjing Liu et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II clinical trial investigated the relationship between TXNRD1 levels and response to tagraxofusp in 12 patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The study found that lower TXNRD1 levels in residual tumor cells were associated with reduced efficacy of tagraxofusp, indicating a potential biomarker for treatment resistance.
Key findings
- Residual tumor cells showed decreased TXNRD1 levels, correlating with reduced tagraxofusp efficacy.
- Responders had wild-type or missense TET2 mutations, while non-responders had truncating TET2 mutations.
- TXNRD1 inhibition led to increased viability of CAL-1 BPDCN cells post-tagraxofusp treatment.
Why it matters
Understanding the molecular mechanisms underlying resistance to tagraxofusp can help identify patients who may benefit from alternative therapies or combination strategies, ultimately improving treatment outcomes in BPDCN.